CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

达拉图穆马 抗体依赖性细胞介导的细胞毒性 CD38 CD16 癌症研究 免疫学 多发性骨髓瘤 免疫疗法 抗体 生物 免疫系统 单克隆抗体 干细胞 CD8型 细胞生物学 川地34 CD3型
作者
Karrune V. Woan,Ryan Bjordahl,Frank M. Cichocki,Svetlana Gaidarova,Cameron C. Pride,Dan S. Kaufman,Karl‐Johan Malmberg,Sarah Cooley,Bahram Bob Valamehr,Jeffrey S. Miller
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 3224-3224 被引量:4
标识
DOI:10.1182/blood-2018-99-116459
摘要

Abstract Daratumumab targets the cell surface protein CD38 and is the only FDA approved monoclonal antibody that has demonstrated single agent efficacy in relapsed refractory myeloma. CD38 is broadly expressed in the immune system, and its high expression on multiple myeloma cells allows for effective targeting by daratumumab. Daratumumab induces myeloma cell death through multiple mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and perhaps most importantly, antibody-dependent cellular cytotoxicity (ADCC). ADCC is mediated by binding of the antibody Fc region to the CD16 Fc receptor expressed on natural killer (NK) cells. Engagement of CD16 induces NK cell activation and target cell cytolysis. However, because CD38 is also expressed on the surface of NK cells, daratumumab treatment can induce NK cell fratricide, which likely impairs the effectiveness of ADCC-mediated targeting and elimination of myeloma. In addition, NK cell function is often suppressed or absent in patients with myeloma, as a result of the tumor itself or from its therapy, further reducing the effectiveness of daratumumab. Collectively, preclinical and clinical observations suggest a potential therapeutic benefit of maintaining NK cell numbers and function in patients to support daratumumab-mediated ADCC and augment the treatment of multiple myeloma. We have developed an off-the-shelf NK cell immunotherapy derived from genetically engineered, induced pluripotent stem cells (iPSC) for enhanced ADCC in combination with daratumumab. iPSCs were engineered to express a high-affinity, non-cleavable CD16 construct (hnCD16) in combination with complete bi-allelic disruption of the CD38 gene (hnCD16 CD38-/-), and the engineered iPSCs were subsequently differentiated into NK (iNK) cells. We hypothesized that CD38-deficient iNK cells would exhibit improved survival by avoiding daratumumab-induced NK cell fratricide, while expression of the hnCD16 transgene would enhance ADCC against myeloma cells in combination with daratumumab. Genetic modification was confirmed in hnCD16 CD38-/- iNK cells by flow cytometry, demonstrating abrogation of CD38 expression (Fig. 1A) and constitutive high expression of CD16 (Fig. 1B). Additionally, hnCD16 iNK cells and hnCD16 CD38-/- iNK cells expressed similar levels of SLAMF7/CD319 (the target of elotuzumab) and NKG2A (Fig. 1C and D). No significant difference in iNK cell differentiation, expansion, maturation, activation, or ability to mediate natural cytotoxicity was observed. In contrast to previous reports, we observed no effect of CD38-deficiency on CD16-mediated calcium flux between hnCD16 iNK cells and hnCD16 CD38-/- iNK cells (Figure 1E). In vitro culture of NK cells in the presence of daratumumab led to NK cell fratricide for both peripheral blood-derived NK cells and hnCD16 iNK cells (Fig. 1F). Daratumumab-induced NK cell fratricide was dependent upon expression of both CD16 and CD38, as unmodified iNK with low CD16 levels (~20% of cells) showed reduced cell death in the presence of daratumumab, which was entirely absent in hnCD16 CD38-/- iNK cells (Fig. 1F). This data was confirmed by extended culture of NK cells with RPMI-8226 tumor spheroids in the presence or absence of daratumumab. The number of hnCD16 iNK cells and peripheral blood NK cells were significantly reduced compared to hnCD16 CD38-/- iNK cells (p>0.005, Fig. 1 G). Importantly, hnCD16 CD38-/- iNK cells were better able to mediate ADCC towards MM1.S multiple myeloma cells compared to hnCD16 iNK cells (Fig. 1H). Taken together, these data support our hypothesis that targeted knock out of CD38 on NK cells alleviates daratumumab-induced NK cell fratricide that occurs through the crosslinking of CD16 and CD38 on neighboring NK cells, leading to augmented anti-myeloma immunity. These data provide a translatable, proof of concept study demonstrating precision genetic engineering of iPSC to generate off-the-shelf NK cell immunotherapy to enhance daratumumab mediated ADCC in multiple myeloma. We propose a strategy of off-the-shelf hnCD16 CD38-/- iNK infusion in combination with daratumumab to overcome NK cell depletion effects of CD38 targeted agents and to improve myeloma patient outcomes. Figure 1. Figure 1. Disclosures Bjordahl: Fate Therapeutics Inc.: Employment. Cichocki:Fate Therapeutics Inc.: Consultancy, Research Funding. Gaidarova:Fate Therapeutics Inc: Employment. Pride:Fate Therapeutics Inc.: Employment. Kaufman:Fate Therapeutics: Consultancy, Research Funding. Malmberg:Fate Therapeutics Inc.: Consultancy, Research Funding. Valamehr:Fate Therapeutics Inc.: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
心无杂念完成签到 ,获得积分10
1秒前
LJ_2完成签到 ,获得积分0
8秒前
高贵觅山完成签到,获得积分10
8秒前
keyan完成签到,获得积分10
10秒前
Shulug完成签到 ,获得积分10
10秒前
李可以完成签到 ,获得积分10
12秒前
weven完成签到 ,获得积分10
16秒前
foyefeng完成签到,获得积分10
18秒前
lllll完成签到 ,获得积分10
32秒前
lzr完成签到 ,获得积分10
32秒前
友好的晓曼完成签到,获得积分10
34秒前
白鱼neko完成签到 ,获得积分10
35秒前
木卫二完成签到 ,获得积分10
37秒前
xiaoxiao完成签到 ,获得积分10
38秒前
momo完成签到 ,获得积分10
39秒前
风格完成签到,获得积分10
48秒前
48秒前
水煮电吹风的应助被雪山飞龙采纳,获得10
49秒前
醉酒当歌完成签到 ,获得积分10
50秒前
侯子完成签到 ,获得积分10
50秒前
追寻微笑完成签到 ,获得积分10
50秒前
勤劳的唇膏完成签到,获得积分10
54秒前
taowenquan完成签到 ,获得积分10
1分钟前
旅行者N0501完成签到,获得积分10
1分钟前
灵巧的长颈鹿完成签到,获得积分10
1分钟前
怼怼完成签到 ,获得积分10
1分钟前
nikki完成签到 ,获得积分10
1分钟前
马伯乐完成签到 ,获得积分10
1分钟前
Hello的应助被豆豆采纳,获得10
1分钟前
1分钟前
动人的冷霜完成签到,获得积分10
1分钟前
迅速的新竹完成签到,获得积分10
1分钟前
Peiqi的应助被雪山飞龙采纳,获得10
1分钟前
1分钟前
蓝精灵完成签到,获得积分10
1分钟前
yuki完成签到 ,获得积分10
1分钟前
漾漾的羊完成签到 ,获得积分10
1分钟前
dianeil完成签到,获得积分10
1分钟前
王不凡完成签到 ,获得积分10
1分钟前
LWJ完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180053
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808682
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012